Clinical Applications for Estetrol Visser M, Coelingh Bennink HJT J

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Applications for Estetrol Visser M, Coelingh Bennink HJT J Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Clinical Applications for Estetrol Visser M, Coelingh Bennink HJT J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 56-60 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Clinical Applications for Estetrol # Clinical Applications for Estetrol * M. Visser, H. J. T. Coelingh Bennink In this paper the potential clinical applications for the human fetal estrogen estetrol (E4) are presented based on recently obtained data in preclinical and clinical studies. In the past E4 has been classified as a weak estrogen due to its rather low estrogen receptor affinity. However, recent research has demonstrated that due to its favorable pharmacokinetic properties, especially the slow elimination and long half-life, E4 is an effective orally bioavailable estrogen agonist with estrogen antagonistic effects on the breast in the presence of estradiol. Based on the pharmacokinetic properties, the pharmaco- logical profile and the safety and efficacy results in human studies, E4 seems potentially suitable as a drug for human use in applications such as hormone replacement therapy (vaginal atrophy and vasomotor symptoms), contraception, osteoporosis and breast cancer J Reproduktionsmed Endokrinol 2010; 7 (Special Issue 1): 56–60. Key words: estetrol, E4, clinical applications Introduction [10–14]. More details on the history of tradiol showed the most prominent in- E4 and data from studies in the period crease in the production of SHBG, while Estetrol (E4) is a human steroid, pro- from 1965 to 1984 have been summa- E3 and EE showed a lower and compa- duced by the fetal liver during pregnancy rized in two review papers [8, 15]. rable increase in SHBG. In addition no only. This natural hormone was discov- detectable binding of E4 was found to ered in urine of pregnant women by During the last 7 years E4 has been stud- both the estrogenic and androgenic hu- Diczfalusy and coworkers in 1965 [1]. ied extensively. High oral absorption man SHBG steroid-binding sites [19]. Based on its physical and chemical char- and bioavailability with a 2–3 h elimina- Both testosterone and E2 were bound acteristics it was concluded that E4 is tion half-life in the rat has been estab- with high affinity, whereas EE bound to identical with 15α-hydroxyestriol (15α- lished [16]. In the human E4 showed a SHBG with low affinity [19]. These re- OHE3) or estra-1, 3, 5(10)-triene-3,15α-, high and dose-proportional oral bio- sults indicate that the plasma distribution 16α-, 17β-tetrol [2]. Estetrol has the availability and a remarkably long termi- of E4 or its availability for target tissues structure of an estrogenic steroid with nal elimination half-life of about 28 h may not be affected by SHBG levels in four hydroxyl groups which explains the [17]. contrast to other natural steroids such as acronym E4. Estetrol is synthesized by E2 and testosterone. the fetal liver during human pregnancy Estetrol has a moderate affinity for both and reaches the maternal circulation human ERα and ERβ receptors with a Estetrol has also been studied in predic- through the placenta. The fetal liver is 4–5-fold preference for the ERα [18]. In tive, validated, pharmacological in vivo the exclusive site of 15α- and 16α- addition it was found that E4 binds highly rat models and in phases I and IIA clini- hydroxylation [3–5]. After birth the neo- selectively to the estrogen receptors. cal trials in the human females. This data natal liver rapidly looses its capacity to indicate that E4 may be suitable for use synthesize E4. In rat and human hepatocytes the rate of in several indications, e. g. hormone re- E4 metabolism was studied and found to placement therapy (vasomotor symp- Estetrol was already detected at 9 weeks be slow [18]. In addition E4 did not in- toms and vaginal atrophy), contracep- of pregnancy in maternal urine [6, 7]. hibit any of the major drug metabolizing tion, osteoporosis and breast cancer. In During the second trimester of preg- cytochrome P450 enzymes CYP1A2, the current paper these potential clinical nancy high levels were found in mater- CYP2C9, CYP2C19, CYP2D6 and applications of E4 are reviewed based on nal plasma, with steadily rising concen- CYP3A4 at a high concentration of data generated from pharmacological trations of unconjugated E4 to about 10 µM [18]. This in contrast with the studies as well as clinical trials per- 1 ng/mL (3 nmol/L) towards the end of effects of estradiol (E2) and ethinyl- formed with E4. pregnancy [8, 9]. So far the physiologi- estradiol (EE) on these enzymes. cal function of E has not been studied 4 Vasomotor Symptoms and is unknown. Using the HepG2 and Hep89 cell lines the ERα-dependent effect of E2, estriol The efficacy of E4 in alleviating hot The possible use of E4 as a marker for (E3), E4 and EE on SHBG production flushes was studied in an experimental fetal well-being has been studied quite was investigated [19]. Estetrol did not rat model considered representative for extensively. However, due to the large stimulate the production of SHBG in menopausal vasomotor symptoms [20]. intra- and interindividual variation of both cell lines, while E2, E3 and EE all maternal E4 plasma levels during preg- showed a dose-dependent ERα-medi- In this model the thermal responses in nancy this appeared not to be feasible ated increase in SHBG production. Es- the tail skin of morphine-dependent * Reprint of: J Steroid Biochem Mol Biol 2009; 114: 85–9. Reprint with permission from Elsevier. © 2009 Elsevier Ltd. All rights reserved. # Lecture presented at the 18th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, 18–21 September 2008, Seefeld, Tyrol, Austria. Correspondence: Monique Visser, Pantarhei Bioscience B. V. Boslaan 11, NL-3701 CH Zeist, The Netherlands; e-mail: [email protected] 56 J Reproduktionsmed Endokrinol 2010; 7 (Special Issue 1) For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH. Clinical Applications for Estetrol ovariectomised (OVX) rats was re- corded after administration of naloxone (NAL). Six groups of rats were treated orally for 8 days as follows: vehicle (negative) control; E4: 0.1, 0.3, 1.0 and 3.0 mg/(kg day) and as active (positive) control EE: 0.3 mg/(kg day). On day 8, tail skin temperature (TST) was recorded at baseline and for 60 min at 5-min inter- vals following NAL administration. In control animals TST increased sharply by about 4.5 °C after NAL treatment and reverted to baseline by 60 min. Estetrol suppressed the TST increase in a dose- dependent fashion (Fig. 1). The highest dose of E4 tested (3 mg/[kg day]) was equipotent to a 10-fold lower dose of EE. Both fully suppressed TST changes [20]. Figure 1: The effects of estetrol and ethinylestradiol on the hot flush response induced by naloxone in female ova- riectomised rats. It is concluded that E4 is effective in pre- venting temperature rises in an experi- mental animal model considered repre- sentative for studying the effect of drugs on the menopausal hot flush (vasomotor symptoms). In this model the potency of E4 was 10-fold lower compared to EE. A phase I multiple dose study to evaluate the safety, tolerability, pharmacokinet- ics and pharmacodynamics of four dos- ages of E4 after daily administration for 28 days was performed in healthy post- menopausal women (unpublished data). In the 2 and 10 mg/day E4 dose groups women were included with at least 30 hot flushes per week. Estetrol was effec- tive in alleviating hot flushes in most women in both dose groups comparable with a 2 mg/day E -valerate control 2 Figure 2: Number of animals with vaginal cornification over a 7-day treatment period with orally administered group during the treatment period of estetrol (E4; 0.1, 0.3, 1.0 or 3.0 mg/(kg day)), ethinylestradiol. 4 weeks. Although the level of evidence of this study design is not high, it indi- cates efficacy at these dose levels. was determined. Vaginal cornification induced dose-dependent increases in was observed by day 5 in all rats at all uterine weight of OVX rats. The potency These results suggest that E4 may be ef- E4 doses and in the animals receiving of EE in increasing uterine weight in this fective for the treatment of hot flushes EE, but not in the control rats (Fig. 2). model was 5–25 times higher than that of and other vasomotor symptoms in peri- The onset of cornification with E4 was E4. and postmenopausal women. dose-dependent. After 7 days treatment, the 2 highest E4 doses (1.0 and 3.0 mg) In addition, estetrol showed a dose-de- Vaginal Atrophy induced statistically significantly higher pendent proliferative estrogenic effect uterine wet weight (myometrium) com- on the rat endometrium after 4 weeks The effect of E4 on vaginal cornification pared to vehicle [21].
Recommended publications
  • Memorandum Date: June 6, 2014
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M.
    [Show full text]
  • Estetrol: New Perspectives for HRT in Menopause and Breast Cancer
    Graziottin A. Singer C. Kubista E. Visser M. Coelingh Bennink H. Estetrol: new perspectives for HRT in menopause and breast cancer patients V Annual International Congress on Human Reproduction on "Family Reproductive Health", Moscow, Russia, January 18-21, 2011 Estetrol: new perspectives for HRT in menopause and breast cancer patients Alessandra Graziottin *, Christian Singer **, Ernst Kubista **, Monique Visser *** and Herjan J.T. Coelingh Bennink *** * Professor at the University of Florence, Italy – Director, Center of Gynaecology, H San Raffaele Resnati, Milan, Italy ** Akademisches Krankenhaus Wien, Wien, Austria *** Pantarhei Bioscience, Zeist, The Netherlands Estetrol (E 4) is a foetal estrogen, produced by the foetal liver during pregnancy only. It has a selective ERalpha and ERbeta receptor bindin g with preference for ERalpha, with antagonist action. E 4 is present at 9 weeks of gestation, with exponential increase of synthesis and blood levels. At term the foetus produces about 3 mg/day. Elimination half-life is 28 hours. Potential applications in women’s life-span include: contraception, hormone replacement therapy (HRT), specifically for vasomotor symptoms, vulvovaginal atrophy and osteoporosis, and therapy of breast cancer. Preliminary data support its efficacy in the treatment of: hot flushes, with significant reduction; in the maturation of the vaginal mucosa, with significant increase of superficial cells at the cytological evaluation; a dose dependent effect on the endometrium: low doses such as 2 mg of Estetrol/day, sufficient to treat a number of symptoms, do not stimulate the endometrium; a significant protective effect on bone: this growing set of data suggest that E 4 could have a new, significant role in the treatment of menopausal symptoms, with an extraordinary safe profile.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • Estrogen Pharmacology. I. the Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man
    Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man Mark N. Mueller, Attallah Kappas J Clin Invest. 1964;43(10):1905-1914. https://doi.org/10.1172/JCI105064. Research Article Find the latest version: https://jci.me/105064/pdf Journal of Clinical Investigation Vol. 43, No. 10, 1964 Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) inMan* MARK N. MUELLER t AND ATTALLAH KAPPAS + WITH THE TECHNICAL ASSISTANCE OF EVELYN DAMGAARD (From the Department of Medicine and the Argonne Cancer Research Hospital,§ the University of Chicago, Chicago, Ill.) This report 1 describes the influence of natural biological action of natural estrogens in man, fur- estrogens on liver function, with special reference ther substantiate the role of the liver as a site of to sulfobromophthalein (BSP) excretion, in man. action of these hormones (5), and probably ac- Pharmacological amounts of the hormone estradiol count, in part, for the impairment of BSP dis- consistently induced alterations in BSP disposal posal that characterizes pregnancy (6) and the that were shown, through the techniques of neonatal period (7-10). Wheeler and associates (2, 3), to result from profound depression of the hepatic secretory Methods dye. Chro- transport maximum (Tm) for the Steroid solutions were prepared by dissolving crystal- matographic analysis of plasma BSP components line estradiol and estriol in a solvent vehicle containing revealed increased amounts of BSP conjugates 10% N,NDMA (N,N-dimethylacetamide) 3 in propylene during estrogen as compared with control pe- glycol. Estradiol was soluble in a concentration of 100 riods, implying a hormonal effect on cellular proc- mg per ml; estriol, in a concentration of 20 mg per ml.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : the Unique Potential of Estetrol
    investor day 2016 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : The unique potential of Estetrol 10 :30 – 11 :45Programme: Mithra’sde la journée strategy 11 :45 – 12 :00 : Q&A 12 :00 – 13 :30 : Drink and lunch with Executive Management 13 :30 – 14 :15 : Focus on Estetrol-based projects 14 :15 – 14 :30 : Coffee break 14 :30 – 15 :15 : Focus on long-acting drugs and Mithra CDMO 15 :15 – 15 :30 : Q&A and wrap-up session 15 :30 – 16 :30 : Drink and networking What is Estetrol ? Interview with Professor J.M. Foidart MD. Member of scientific committee Mithra Professor J.M. Foidart MD. Member of scientific committee Mithra 4 Estrogens in the “pill” a very limited family . Estradiol . Synthetic progestin . Ethinylestradiol Over 95% of oral contraceptives contain ethinylestradiol 6 Synthetic Progestins : a very large family First First Second Third New” COCs generation: generation: generation: progestins: > Norethisterone > Norethynodrel > Norgestrel > Desogestrel > Drospirenone > Norethinodrel > Nortestosterone > Levonorgestrel > Etonogestrel > Dienogest > High doses of derivatives > Gestodene > Trimestone synthetic estrogen >Pregnanes > Nesterone and androgenic > Norgestimate > Nomegestrol Ac. progestin > Promegestone Jan 2014 EMA classification progestins by type . Structural modification: to reduce androgenic side-effects but maintain strong progestational activity . Wider health benefits depending on progestin properties Reviewed in Brynhildsen J. Ther Adv Drug Saf. 2014;5(5):201-13; Benagiano7 G, et al. Eur J Contracept Reprod Health Care. 2004;9(3):182- 93; Sitruk-Ware R. Hum Reprod Update. 2006;12(2):169-78; Micks E, et al. Endocr Connect. 2015;4(4):R81-92 The third and fourth generation progestins and pills are not androgenic.
    [Show full text]
  • The Structural Biology of Oestrogen Metabolism
    Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 27–49 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology jo urnal homepage: www.elsevier.com/locate/jsbmb Review The structural biology of oestrogen metabolism ∗ Mark P. Thomas, Barry V.L. Potter Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK a r t i c l e i n f o a b s t r a c t Article history: Many enzymes catalyse reactions that have an oestrogen as a substrate and/or a product. The reac- Received 11 September 2012 tions catalysed include aromatisation, oxidation, reduction, sulfonation, desulfonation, hydroxylation Received in revised form and methoxylation. The enzymes that catalyse these reactions must all recognise and bind oestrogen but, 10 December 2012 despite this, they have diverse structures. This review looks at each of these enzymes in turn, describing Accepted 12 December 2012 the structure and discussing the mechanism of the catalysed reaction. Since oestrogen has a role in many disease states inhibition of the enzymes of oestrogen metabolism may have an impact on the state or Keywords: progression of the disease and inhibitors of these enzymes are briefly discussed. Oestrogen This article is part of a Special Issue entitled ‘CSR 2013’. Protein structure © 2012 Elsevier Ltd. Open access under CC BY license. Reaction mechanism Aromatase Sulfatase Sulfotransferase 17␤-Hydroxysteroid dehydrogenase Contents 1. Introduction . 27 2. Methods . 29 3. Oestrogen sulfotransferase . 29 4. Steroid sulfatase. 31 5. 17␤-Hydroxysteroid dehydrogenases . 33 6. Aromatase (cytochrome P450 19A1, oestrogen synthase) . 36 7. Enzymes of steroid hydroxylation .
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide
    Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide Avery A. Sandberg, W. Roy Slaunwhite Jr. J Clin Invest. 1965;44(4):694-702. https://doi.org/10.1172/JCI105181. Research Article Find the latest version: https://jci.me/105181/pdf Journal of Clinical Investigation Vol. 44, No. 4, 1965 Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide * AVERY A. SANDBERG t AND W. RoY SLAUNWHITE, JR. (From the Roswell Park Memorial Institute, Buffalo, N. Y.) Estriol has been considered a metabolic product of enzymes capable of oxidizing the hydroxyl of the more active estrogens, estrone (1, 2) and group at position 16, a finding not reported in the indirectly estradiol. Recently, an alternative path- past. way has been proposed (3) based on the observa- The attention of investigators has recently been tions that 16a-hydroxydehydroepiandrosterone is directed toward steroid conjugates, not only be- present in high concentrations in cord blood and cause they are excreted in that form, but owing to that it is aromatized by placental enzymes. During the demonstration that steroid sulfates may, in pregnancy the placenta has been thought the some instances, serve as biosynthetic intermediates source of the mother's urinary estriol, but recent (12-14), that dehydroepiandrosterone sulfate is evidence indicates that the fetus (4-6) and, in par- secreted by the adrenal cortex (15), that estrone ticular, the fetal liver (7) may play an important circulates in the blood as a sulfate (16), and that role in the conversion of the estrone to estriol steroid sulfates appear to be biologically active (8).
    [Show full text]
  • Estetrol for Menopause Symptoms: the Cinderella of Estrogens Or Just Another Fairy Tale? Nancy King Reame, MSN, Phd, FAAN
    CE: D.C.; MENO-D-20-00177; Total nos of Pages: 3; MENO-D-20-00177 Menopause: The Journal of The North American Menopause Society Vol. 27, No. 8, pp. 000-000 DOI: 10.1097/GME.0000000000001601 ß 2020 by The North American Menopause Society EDITORIAL Estetrol for menopause symptoms: the Cinderella of estrogens or just another fairy tale? Nancy King Reame, MSN, PhD, FAAN espite the advent of lower dosing, transdermal deliv- affinity (<5%) compared to E2.3 Interest was, however, ery, and targeted use in younger age groups, safety renewed in the 2000s when preclinical and pharmacokinetic D concerns persist regarding the potential for estrogen- studies showed that estetrol elicits considerable estrogenic based menopause hormone therapy (MHT) to raise breast effects in rat models for both hot flashes and bone loss, but cancer and thromboembolism risk. In the last few decades a with minimal stimulation of liver and breast.4 More recent wealth of scientific advances has revealed the molecular biol- translational studies5 showed that E4 was bestowed with an ogy of the estrogen receptors (ERs) a and b, opening up new intriguing ER pharmacology, unique from SERMs, thus directions for their pharmaceutical manipulation and promise pushing it to center stage for its potential as the first native to improve hormone therapies. With the help of the ER knock- estrogen with selective action in tissues (NEST). out mouse model, an array of estrogen-mediated actions in Unlike other estrogens, which interact with both a and b tissues throughout the body was elucidated, followed by the receptors at the cell surface and in the nucleus, E4 not only emergence of new compounds with tissue-dependent, ER preferentially binds to the ERa subtype, but does so in a distinct agonistic, antagonistic, and mixed actions.1 Although several non-SERM way.
    [Show full text]
  • Estriol Face Cream Handout
    is used, most of the time it refers to Estradiol Hormone Health (E2), which is the highest concentration --80%-- during a woman's reproductive years (from & Skin Health puberty to pre-menopause). Estriol (E3) makes Dr. Randolph’s NEW up another 10% and Estrone (E1) makes up the last 10%. Estriol Face Cream Estriol (E3) is considered a "weak" estrogen which can be derived from plant sources. It does What is it? not need to be counterbalanced by progesterone, and does not have a systemic (widespread) effect Dr. Randolph's NEW prescription-only Estriol on the body. This makes estriol an ideal estrogen Face Cream consists of Estriol 0.3% , DMAE for topical use, since research suggests its 3%, and Hyaluronic Acid 0.5% mixed in a cream application remains in the skin, rather than in base. Dr. Randolph, along with Compounding the bloodstream. There is also evidence that Pharmacist Will McGalliard, developed this estriol, (sometimes called the "good estrogen") combination of ingredients to provide a may inhibit some of the unwanted effects of clinically-proven treatment that will boost estradiol by "binding" to estrogen receptors that collagen, reduce wrinkles, improve skin moisture typically promote cell proliferation. and elasticity. Who is it for? How does it work? For women or men who wish to improve the One of the many roles of estrogen in the body is appearance and health of their skin by boosting to increase the synthesis of collagen, which is the the development of underlying collagen skin's underlying support structure. Collagen structure, increasing elasticity and skin moisture, also promotes skin thickness and elasticity.
    [Show full text]
  • Drospirenone and Estetrol
    PATIENT & CAREGIVER EDUCATION Drospirenone and Estetrol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Nextstellis Brand Names: Canada Nextstellis Warning Smoking cigarettes while using this drug raises the chance of severe heart and blood-related side effects. This chance is raised with age (mainly older than 35 years of age). It is also raised with the number of cigarettes smoked. It is strongly advised not to smoke. What is this drug used for? It is used to prevent pregnancy. If your child has been given this drug for some other reason, talk with the doctor for more information. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. Drospirenone and Estetrol 1/8 If your child has ever had a very bad or life-threatening reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness. If your child has kidney problems. If your child has adrenal gland problems. If your child has had any of these health problems: Blood clots, blood clotting problem, breast cancer or other cancer where hormones make it grow, diseased blood vessels in the brain or heart, heart valve problems, heart disease, a certain type of abnormal heartbeat (atrial fibrillation), chest pain caused by angina, heart attack, stroke, high blood pressure, liver tumor or other liver problems, severe headache or migraine, or diabetes.
    [Show full text]